Abstract

Thyroid cancer (TC) represents a significant health burden globally, with follicular thyroid cancer (FTC) posing diagnostic challenges despite advancements. This pilot study aimed to evaluate the utility of a liquid biopsy with cell-free DNA (cfDNA) in patients with FTC. Blood samples were collected from 13 patients diagnosed with FTC, DNA extraction was performed, and cfDNA was analyzed using the Illumina's TruSight Oncology 500 High-Throughput panel. The results revealed low tumor mutational burden and minimal pathogenic variants in cfDNA, indicating challenges such as low DNA yield and poor material quality despite adequate coverage. Our findings indicate that cfDNA as an add-on diagnostic tool in patients with FTC might not be a useful supplement.

Original languageEnglish
Article number1577
JournalDiagnostics
Volume14
Issue number14
ISSN2075-4418
Publication statusPublished - 22 Jul 2024

Fingerprint

Dive into the research topics of 'Liquid Biopsies in Follicular Thyroid Carcinomas-A Brief Report'. Together they form a unique fingerprint.

Cite this